OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
37
Results
Show all
Save search
Copy query
Show results for
Unknown
(37)
Publication Date
Release Date
2024
(9)
2021
(4)
2019
(4)
2014
(4)
2023
(3)
2022
(3)
2020
(3)
2018
(3)
2015
(2)
2017
(1)
2013
(1)
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis.
Not available
S-EPMC9581582
|
biostudies-literature
Cite
Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis.
Not available
S-EPMC8487911
|
biostudies-literature
Cite
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
Not available
S-EPMC11111623
|
biostudies-literature
Cite
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
Not available
S-EPMC11111635
|
biostudies-literature
Cite
Positron Emission Tomography Imaging with 2-[
18
F]F- p-Aminobenzoic Acid Detects Staphylococcus aureus Infections and Monitors Drug Response.
Not available
S-EPMC6226330
|
biostudies-literature
Cite
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
Not available
S-EPMC9830619
|
biostudies-literature
Cite
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
Not available
S-EPMC11422334
|
biostudies-literature
Cite
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
Not available
S-EPMC11418537
|
biostudies-literature
Cite
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Not available
S-EPMC9120409
|
biostudies-literature
Cite
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
Not available
S-EPMC11422408
|
biostudies-literature
Cite
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
